Jefferson University Hospitals

Provider Profile

Andrew E. Chapman, DO, FACP

Andrew E. Chapman, DO, FACP

Jefferson University Physician

Academic Title: Clinical Professor
Co-Director, Jefferson Senior Adult Oncology Center
Vice Chair for Clinical Operations, Department of Medical Oncology
Chief of Cancer Services, Sidney Kimmel Cancer Center
Enterprise SVP Medical Oncology, Jefferson Health System

Cancer - Hematologic Malignancies
Cancer - Leukemia/Lymphoma
Geriatric Oncology
Medical Oncology
Medical Oncology - Geriatric Oncology
Medical Oncology - Hematologic Malignancies
Medical Oncology - Leukemia/Lymphoma

Appointment Scheduling

Call 1-800-JEFF-NOW


If you have a Jefferson Health MyChart account you can directly schedule within MyChart.

Online Scheduling

Online scheduling is available for new and existing patients. Existing patients must have seen this provider within the past two years.

More Ways to Get in Touch

Call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

925 Chestnut Street
Suite 420A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 955-9641

Medical Services

Years in Practice


Board Certifications

  • Medical Oncology
  • Hematology

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Methodist Hospital Division of Thomas Jefferson University Hospital

Awards and Honors

Philadelphia Magazine's Top Docs 2018

Personal Statement

I feel that it is of utmost importance to develop a personalized treatment plan for every patient. This treatment plan should encompass the patient's goals in accord with the standards of care for the disease. Additionally, with a particular interest in Geriatric Oncology, I feel that age alone is never a criteria on which a treatment decision should be based.


  • University of Health Sciences - College of Osteopathic Medicine, Medical School


  • Springfield Hospital


  • Penn Presbyterian Medical Center


  • Fox Chase Cancer Center

Jefferson physicians accept most health insurance plans, including those listed below. However, plan acceptance may vary by practice and may be subject to change. If you have questions about whether a specific physician accepts your insurance, please contact your insurance company.

Insurances Accepted

  • Aetna
  • Aetna PA Employee Benefit Trust Fund (PEBTF)
  • Amer Assoc Retired Persons (AARP)
  • AmeriHealth
  • Amerihealth Caritas
  • AmeriHealth Comprehensive
  • AmeriHealth HMO
  • AmeriHealth Major Medical
  • AmeriHealth Personal Choice
  • BC BS Special Care
  • Blue Choice
  • Blue Cross/Blue Shield
  • Blue Cross/Blue Shield of Delaware
  • Cigna Healthspring
  • Cigna PPO, POS
  • Consumer Health Network PPO
  • CorVel
  • Coventry/Health America
  • Delaware Blue Cross/Blue Shield
  • Devon
  • Empire BC/BS
  • Employers Health Network PPO
  • Evolutions (Guardian Resources)
  • Federal BCBS
  • First Health Network
  • Galaxy
  • Geisinger Health Plan
  • Health America PPO
  • Health Management Network PPO
  • Horizon Blue Cross/Blue Shield
  • Horizon HMO
  • HumanaChoicePPO,Medicare,GoldPlusHMO
  • Inter-County Health Plan
  • Intergroup Preferred
  • Jeff Plus
  • Keystone 65 HMO
  • Keystone First VIP Choice
  • Keystone First/Connect
  • Keystone Health Plan East
  • Medallion of New Jersey
  • Medicaid of PA
  • Medicare
  • Mercy LIFE
  • MultiPlan Inc.
  • NJ Blue Shield
  • NJ Plus
  • Oxford of PA
  • Personal Choice (GPPPN)
  • Personal Choice 65
  • PlanCare America
  • Postal Workers/Mailhandlers
  • PPO Next
  • Preferred Care PPO
  • Premier Blue
  • Prime Health Services, Inc.
  • Private Healthcare Systems (PHCS)
  • Qualcare
  • Tricare
  • United Healthcare
  • UPMC HMO,PPO ReadingHspEmpONLY
  • UPMC Medicare HMO
  • US Family Health Plan

Recent Publications

Factors associated with falls in older adults with cancer: a validated model from the Cancer and Aging Research Group

The prevalence of major drug-drug interactions in older adults with cancer and the role of clinical decision support software

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial

Hematology-Oncology fellows' training in geriatrics and geriatric oncology: Findings from an American Society of Clinical Oncology–sponsored national survey

Implementing a pharmacist-led, individualized medication assessment and planning (iMAP) intervention to reduce medication related problems among older adults with cancer

Patient-Centered Specialty Practice: Defining the Role of Specialists in Value-Based Health Care

Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study

Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer

Comorbidity in older adults with cancer

Geriatric assessment with management in cancer care: Current evidence and potential mechanisms for future research

Reply to M.-E. Rougé Bugat et al

A pharmacist-led medication assessment used to determine a more precise estimation of the prevalence of complementary and alternative medication (CAM) use among ambulatory senior adults with cancer

Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer

Predictors of chemotherapy dose reduction at first cycle in patients age 65years and older with solid tumors

Erratum: Silver oncologic tsunami: Quality issues in the senior adult oncology population (Journal of Oncology Practice (2015) 11, (190-192))

Silver oncologic tsunami: Quality issues in the senior adult oncology population

Development of a comprehensive multidisciplinary geriatric oncology center, the Thomas Jefferson university experience

Senior adult oncology: Three cases of advanced cancer in patients of advanced age

Metastatic unknown primary tumor presenting in pregnancy as multiple cerebral infarcts

Phase II: Trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy